Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow

Things are heating up at Flare Therapeutics, with Pfizer, Eli Lilly and Novartis all adding fuel to the biotech’s fire in a new $123 million financing round.

“We’re the only company focused on transcription factors as prime therapeutic targets,” Flare CEO Amit Rakhit, M.D., told Fierce Biotech in an interview.